Brynn E. Marks, MD, MSHPEd
Assistant Professor of Pediatrics (Endocrinology and Diabetes) at the Children's Hospital of Philadelphia
Attending Physician, Division of Endocrinology & Diabetes, Children's Hospital of Philadelphia
Director of Technology, Diabetes Center, Children's Hospital of Philadelphia
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Division of Endocrinology and Diabetes
The Hub for Clinical Collaboration
3501 Civic Center Boulevard
7th Floor, Office 7547
Philadelphia, PA 19104
Office: 267-426-4925
Publications
Education:
BA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
Permanent linkBA (Psychology)
Georgetown University, 2007.
MD
Thomas Jefferson University Sidney Kimmel Medical College, 2011.
MSHPEd
Massachusetts General Hospital Institute of Health Professions, 2019.
Description of Clinical Expertise
type 1 diabetes, cystic fibrosis-related diabetes, post-transplant diabetesDescription of Research Expertise
type 1 diabetes, cystic fibrosis-related diabetes, diabetes technology, automated insulin delivery, continuous glucose monitor, insulin pump, medical education, healthcare inequitiesSelected Publications
Iyer J, Meighan S, Marks BE: Pediatric Endocrinology Trainees’ Education and Knowledge about Automated Insulin Delivery Systems. American Diabetes Association 85th Scientific Sessions, Chicago, Illinois June 2025.Meighan S, Johnson D, Gallop RJ, Kelly A, Putman MS, Marks BE: Alternative approaches to glucose measurement during oral glucose tolerance testing in youth with cystic fibrosis. American Diabetes Association 85th Scientific Sessions, Chicago, Illinois June 2025.
Meighan S, Lipman T, VanGraafeiland B, Marks BE: Continuous Glucose Monitoring Attrition in Youth with Type 1 Diabetes. Sci Diabetes Self Manag Care Feb 2025.
Gera S, Rearson A, Baker G, Douvas J, Alicea Trelles N, Gallop R, Meighan S, Marks BE: Changes in 90-day Time in Range among Youth with Type 1 Diabetes Initiating Different Automated Insulin Delivery Systems. J Clin Endocrinol Metab Jan 2025.
Wolf R, Patel D, Gera S, Molano G, DOliveira T, Meighan S, Brown E, Marks BE: Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control between White and Black Youth with Type 1 Diabetes? Diabetes Technology & Therapeutics in press 2025.
Scully KJ, Reed M, Douvas J, Putman MS, Marks BE: The Effect of Omnipod 5 Automated Insulin Delivery on Glycemic Control in Adolescents and Adults with Cystic Fibrosis-Related Diabetes. Diabetes Technology & Therapeutics in press 2025.
Vitale RJ, Ford C, Scully K, Marks B, Putman M: Sleep, body image, and mental health outcomes among people with and without cystic fibrosis-related diabetes in the yETI study. North American Cystic Fibrosis Conference, Seattle, WA 2025.
Brynn E. Marks, Seema Meighan, Emily Fivekiller, Estella Escobar, Cari Berget: Ketone Management in Pediatric Diabetes Centers in the United States: Current Practices and a call for Improved Standardization Hormone Research in Pediatrics 15(1): 1-9, Oct 2024.
Meighan S, Douvas JL, Rearson A, Squaresky R, Kelly A, Marks BE: The type of patient training does not impact outcomes in the first 90 days of automated insulin delivery use. Diabetes Technology and Therapeutics 26(10): 773-779, Oct 2024.
Scully KJ, Marks BE, Putman MS. : Advances in diabetes technology to improve the lives of people with cystic fibrosis. Diabetologia 67(10): 2143-2153, Oct 2024.